Medunik Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MEDUNIK
MEDUNIK has two approved drugs.
Drugs and US Patents for Medunik
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medunik | NITISINONE | nitisinone | CAPSULE;ORAL | 212390-002 | May 26, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medunik | NITISINONE | nitisinone | CAPSULE;ORAL | 212390-003 | May 26, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Medunik | PHEBURANE | sodium phenylbutyrate | PELLETS;ORAL | 216513-001 | Jun 17, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

